Literature DB >> 18853098

Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes?

Sandra Fernanda Nunes1, Isabel Vitoria Figueiredo, Paulo João Soares, Nuria Espriu Costa, Maria Celeste Lopes, Maria Margarida Caramona.   

Abstract

The aim of this study was to evaluate the activity of semicarbazide-sensitive amine oxidase (SSAO) and the total nitrite and nitrate (NO( x )) concentrations in serum from type 2 diabetic patients and control subjects in order to evaluate if they could be used as novel diabetic markers. We studied 38 type 2 diabetic patients and 35 control subjects. Serum samples from those subjects were evaluated by radiochemical methods for SSAO activity using (14)C-benzylamine. Serum NO( x ) concentrations were obtained as an index of nitric oxide production by the Griess reaction. Serum SSAO activity was higher in type 2 diabetic patients than in control group and serum SSAO in type 2 diabetic correlated with age, serum creatinine and total cholesterol. Serum NO( x ) levels in type 2 diabetic patients were also significantly higher than those in the control group. Serum NO( x ) levels in control group correlated with serum SSAO activity. In conclusion, the increase in the SSAO activity and NO( x ) levels observed in type 2 diabetic patients could be parameters to take in account and play relevant role in diabetes development. SSAO and NO( x ) are suggested as markers for prognostic of diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853098     DOI: 10.1007/s00592-008-0070-7

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Anatomical distribution of primary amine oxidase activity in four adipose depots and plasma of severely obese women with or without a dysmetabolic profile.

Authors:  Christian Carpéné; Francisco Les; Mounia Hasnaoui; Simon Biron; Picard Marceau; Denis Richard; Jean Galitzky; Denis R Joanisse; Pascale Mauriège
Journal:  J Physiol Biochem       Date:  2016-10-21       Impact factor: 4.158

2.  Development of a HPLC-FL method to determine benzaldehyde after derivatization with N-acetylhydrazine acridone and its application for determination of semicarbazide-sensitive amine oxidase activity in human serum.

Authors:  Xiuli Dong; Jiayuan Tang; Yan Ren; Xiangming Chen
Journal:  RSC Adv       Date:  2019-02-26       Impact factor: 4.036

3.  Correlation between total nitrite/nitrate concentrations and monoamine oxidase (types A and B) and semicarbazide-sensitive amine oxidase enzymatic activities in human mesenteric arteries from non-diabetic and type 2 diabetic patients.

Authors:  S F Nunes; I V Figueiredo; J S Pereira; M C Lopes; M M Caramona
Journal:  Braz J Med Biol Res       Date:  2011-11-25       Impact factor: 2.590

Review 4.  Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.

Authors:  Dimitri Papukashvili; Nino Rcheulishvili; Yulin Deng
Journal:  Molecules       Date:  2020-04-27       Impact factor: 4.411

5.  Effects of semicarbazide-sensitive amine oxidase inhibitors on morphology of aorta and kidney in diabetic rats.

Authors:  Chaosheng Li; Zhenhua Wang; Xiaoli Li; Jun Chen
Journal:  BMC Endocr Disord       Date:  2019-06-10       Impact factor: 2.763

6.  Increased atherosclerotic plaque in AOC3 knock-out in ApoE-/- mice and characterization of AOC3 in atherosclerotic human coronary arteries.

Authors:  Anna Filip; Soraya Taleb; Rümeyza Bascetin; Mohammad Jahangiri; Matthieu Bardin; Cindy Lerognon; Bruno Fève; Patrick Lacolley; Sirpa Jalkanen; Nathalie Mercier
Journal:  Front Cardiovasc Med       Date:  2022-09-13

7.  The effect of high-dose insulin analog initiation therapy on lipid peroxidation products and oxidative stress markers in type 2 diabetic patients.

Authors:  Hazal Tuzcu; Ibrahim Aslan; Mutay Aslan
Journal:  Oxid Med Cell Longev       Date:  2013-03-17       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.